|
| 36152015 | Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study. | Hepatology | 2023 |
| 38000030 | Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer. | Sci Adv | 2023 |
| 37648323 | Pemetrexed and Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer Who Failed Gemcitabine-containing Chemotherapy: A Phase II Single-arm Prospective Study. | Anticancer Res | 2023 |
| 37935099 | Smoking Cessation and Pancreatic Cancer Risk in Individuals With Prediabetes and Diabetes: A Nationwide Cohort Study. | J Natl Compr Canc Netw | 2023 |
| 37499191 | Clinical Implication of <i>HER2</i> Aberration in Patients With Metastatic Cancer Using Next-Generation Sequencing: A Pan-Tumor Analysis. | JCO Precis Oncol | 2023 |
| 35681110 | A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer. | Cancer Res Treat | 2023 |
| 37075279 | Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study. | J Clin Oncol | 2023 |
| 37163165 | The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation. | Therap Adv Gastroenterol | 2023 |
| 36521097 | Adjuvant <i>nab</i>-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. | J Clin Oncol | 2023 |
| 36650632 | Comprehensive immunoprofile analysis of prognostic markers in pancreaticobiliary tract cancers. | Cancer Med | 2023 |
| 36765032 | Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-β signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors. | Cell Death Dis | 2023 |
| 34132691 | Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinoma. | Ann Surg | 2022 |
| 35377061 | Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer. | Ann Surg Oncol | 2022 |
| 35834777 | Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. | J Clin Oncol | 2022 |
| 35342406 | Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing. | J Oncol | 2022 |
| 35696635 | Light-to-Moderate Alcohol Consumption Increases the Risk of Biliary Tract Cancer in Prediabetes and Diabetes, but Not in Normoglycemic Status: A Nationwide Cohort Study. | J Clin Oncol | 2022 |
| 35850192 | An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. | Gastroenterology | 2022 |
| 36483096 | MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer. | Pathol Oncol Res | 2022 |
| 35992188 | Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer. | Therap Adv Gastroenterol | 2022 |
| 36230475 | The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer. | Cancers (Basel) | 2022 |
| 35252005 | HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer. | Front Oncol | 2022 |
| 34980153 | A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology. | Mol Cancer | 2022 |
| 35248464 | A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. | Clin Oncol (R Coll Radiol) | 2022 |
| 35065369 | Association between alcohol consumption and pancreatic cancer risk differs by glycaemic status: A nationwide cohort study. | Eur J Cancer | 2022 |
| 34551969 | Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study. | Cancer Discov | 2022 |
| 34510272 | The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. | J Cancer Res Clin Oncol | 2022 |
| 34653420 | Changes in Metabolic Syndrome Status are Associated With Altered Risk of Pancreatic Cancer: A Nationwide Cohort Study. | Gastroenterology | 2022 |
| 33391442 | Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer. | J Cancer | 2021 |
| 33854995 | CORRIGENDUM: Addition of data source: Diagnostic model for pancreatic cancer using a multi-biomarker panel. | Ann Surg Treat Res | 2021 |
| 33717226 | Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. | Ther Adv Med Oncol | 2021 |
| 33730723 | Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. | Oncology | 2021 |
| 33555926 | Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). | J Clin Oncol | 2021 |
| 33748028 | Diagnostic model for pancreatic cancer using a multi-biomarker panel. | Ann Surg Treat Res | 2021 |
| 33916008 | Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review. | Cancers (Basel) | 2021 |
| 33578192 | Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG). | ESMO Open | 2021 |
| 34855561 | Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer. | Technol Cancer Res Treat | 2021 |
| 34474218 | Role of adjuvant radiotherapy in extrahepatic bile duct cancer: A multicenter retrospective study (Korean Radiation Oncology Group 18-14). | Eur J Cancer | 2021 |
| 34471425 | Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. | Ther Adv Med Oncol | 2021 |
| 34371446 | Persistent status of metabolic syndrome and risk of cholangiocarcinoma: A Korean nationwide population-based cohort study. | Eur J Cancer | 2021 |
| 34371066 | Association of prediabetes, diabetes, and diabetes duration with biliary tract cancer risk: A nationwide cohort study. | Metabolism | 2021 |
| 33975862 | Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. | Clin Cancer Res | 2021 |
| 33402502 | ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy. | In Vivo | 2021 |
| 33278599 | A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial<sup>â¿¿</sup>. | Ann Oncol | 2021 |
| 31588705 | Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer. | Cancer Res Treat | 2020 |
| 35117702 | Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. | Transl Cancer Res | 2020 |
| 31789476 | Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. | Cancer Sci | 2020 |
| 31964553 | TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. | Pathol Res Pract | 2020 |
| 32076068 | Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models. | Sci Rep | 2020 |
| 32073954 | Geographic and Ethnic Heterogeneity of Germline <i>BRCA1</i> or <i>BRCA2</i> Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. | J Clin Oncol | 2020 |
| 32070411 | Comprehensive pharmacogenomic characterization of gastric cancer. | Genome Med | 2020 |